#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Czecho-Slovak Pathology / 2024 - 4

Atypical Endometriosis – An Overview of the Issue and Personal Experiences

Czech version

Authors: Jiří Lenz 1,2
Authors‘ workplace: Patologicko-anatomické oddělení, Nemocnice Znojmo 2 Ústav anatomie, histologie a embryologie, Fakulta veterinárního lékařství, Veterinární univerzita Brno
Published in: Čes.-slov. Patol., 60, 2024, No. 4, p. 185-192
Category: Original Article

Overview

Endometriosis is a chronic, estrogen-dependent, inflammatory disease characterized by the growth of endometriotic tissue outside the uterus. Among the wide spectrum of clinical manifestations of endometriosis, chronic pelvic pain, dysmenorrhea, dyspareunia and subfertility are the main symptoms that significantly reduce the quality of life of affected women. Despite the fact that endometriosis is considered a benign disease, it shares some features typical of malignant tumors. One of them is abnormal morphology, which indicates atypia of the glandular epithelium without signs of hyperplasia, or it may be glandular hyperplasia, which may or may not be accompanied by cellular atypia. This situation is reflected in the term atypical endometriosis, the diagnosis of which is not easy. Cellular atypia of a severe degree can be of reactive origin, so the mutual differentiation of dysplastic and reactive changes in endometriotic tissue is limited and problematic. Our working group from the scientific center for the treatment of endometriosis at the Znojmo Hospital recently dealt with atypical endometriosis and pointed out the potential utility of immunohistochemistry in its diagnosing. Using a simple immunohistochemical panel with antibodies against estrogen receptors, progesterone receptors, and the tumor suppressor p53, we found significantly lower levels of hormone receptor expression and increased p53 expression in atypical endometriosis compared to normal (typical) endometriosis. Due to the low number of cases analyzed and the inconsistent results of studies dealing with hormone receptors (and other markers) in atypical endometriosis, the usefulness of the immunohistochemical panel described in our study must be verified on a larger number of cases. In routine histopathological practice, atypical endometriosis is not a well-known entity. However, it is important to become familiar with it because its presence is associated with a higher incidence of a certain group of tumors known as endometriosis-associated cancers, especially endometrioid carcinoma and clear cell carcinoma.

Keywords:

immunohistochemistry – p53 – atypical endometriosis – endometriosis-associated ovarian cancer – hormone receptors

Sources
  1. Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann N Y Acad Sci 2002; 955: 11-22; discussion 34-6, 396-406.
  2. Lenz J, Chvátal R, Fiala L, eds. Endometrióza. Grada Publishing; 2021: 25-57.
  3. Thomas EJ, Campbell IG. Molecular genetic defects in endometriosis. Gynecol Obstet Incest 2000; 50 Suppl 1: 44-50.
  4. Sampson JA. Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg 1925; 10:1.
  5. Scott RB. Malignant changes in endometriosis. Obstet Gynecol 1953; 2(3): 283-289.
  6. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 2012;124(1):164169.
  7. Matias-Guiu X, Stewart CJ. Endometriosisassociated ovarian neoplasia. Pathology 2018; 50(2): 190–204.
  8. Buis CC, van Leeuwen FE, Mooij TM, Burger CW; OMEGA Project Group. Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis. Hum Reprod 2013; 28(12): 3358-3369.
  9. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control 2008; 19(10): 1357-1364.
  10. Oral E, Ilvan S, Tustas E, et al. Prevalence of endometriosis in malignant epithelial ovary tumours. Eur J Obstet Gynecol Reprod Biol 2003; 109(1): 97-101.
  11. Brinton LA, Sakoda LC, Sherman ME, et al. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev 2005; 14(12): 2929-2935.
  12. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13(4): 385-394.
  13. Ho RS, Chan GC, Ha SY, Ip PP. Endometriosisassociated serous borderline tumor and endometrial stromal sarcoma of the ovary: a report of a rare lesion in an infant. Int J Gynecol Pathol 2012; 31(1): 98-102.
  14. Mikami, Y. Endometriosis-related ovarian neoplasms: Pathogenesis and histopathologic features. Diagn Histopathol 2014; 20: 357–363.
  15. Ñiguez Sevilla I, Machado Linde F, Marín Sánchez MDP, et al. Prognostic importance of atypical endometriosis with architectural hyperplasia versus cytologic atypia in endometriosisassociated ovarian cancer. J Gynecol Oncol 2019;30(4):e63.
  16. Wepy C, Nucci MR, Parra-Herran C. Atypical Endometriosis: Comprehensive Characterization of Clinicopathologic, Immunohistochemical, and Molecular Features. Int J Gynecol Pathol 2024; 43(1): 70-77.
  17. Stewart CJR, Ayhan A, Fukunaga M, Huntsman DG. Endometriosis and related conditions. In: WHO Classification of Tumours Editorial Board. Female genital tumours (5th ed). Lyon (France): International Agency for Research on Cancer; 2020: 170173.
  18. Czernobilsky B, Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol 1979; 53(3): 318-323.
  19. LaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. Hum Pathol 1988; 19(9): 1080-1084.
  20. Větvička V, Fiala L, Garzon S, Buzzaccarini G, Terzic M, Laganà AS. Endometriosis and gynaecological cancers: Molecular insights behind a complex machinery. Prz. Menopauzalny 2021; 20(4): 201–206.
  21. Wiegand KC, Shah SP, Al-Agha OMet al. ARID1AMutations in EndometriosisAssociated Ovarian Carcinomas. N Engl J Med 2010; 363(16): 1532–1543.
  22. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011; 224(3): 328–333.
  23. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: Possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000; 60(24): 7052–7056.
  24. Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011; 225: 189–194.
  25. Kato N, Sasou SI Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2005; 19(1): 83–89.
  26. Fujimura M, Hidaka T, Kataoka K, et al. Absence of Estrogen Receptor-Expression in Human Ovarian Clear Cell Adenocarcinoma Comparedwith Ovarian Serous, Endometrioid, and Mucinous Adenocarcinoma. Am J Surg Pathol 2001; 25(5): 667–672.
 
  1. Akahane T, Sekizawa A, Purwosunu Y, Nagatsuka M, Okai T. The Role of p53 Mutation in the Carcinomas Arising from Endometriosis. Int J Gynecol Pathol 2007; 26(3): 345–351.
  2. Lenz J, Chvátal R, Fiala L, Konečná P, Lenz D. Comparative immunohistochemical study of deep infiltrating endometriosis, lymph node endometriosis and atypical ovarian endometriosis including description of a perineural invasion. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021; 165(1): 69-79.
  3. Schenken RS, Guzick DS. Revised endometriosis classification: 1996. Fertil Steril 1997; 67(5): 815-816.
  4. Johnson NP, Hummelshoj L, Adamson GD, et al. World Endometriosis Society Sao Paulo Consortium. Hum Reprod 2017; 32(2): 315-324.
  5. Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol. 2019;38 Suppl 1(Iss 1 Suppl 1): S123-S131.
  6. Xiao W, Awadallah A, Xin W. Loss of ARID1A/ BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int. J. Clin. Exp. Pathol 2012; 5(7): 642–650.
  7. Lin K, Zhan H, Ma J, et al. Increased steroid receptor RNA activator protein (SRAP) accompanied by decreased estrogen receptor-beta (ER-β) levels during the malignant transformation of endometriosis associated ovarian clear cell carcinoma. Acta Histochem 2014; 116(5): 878–882.
  8. Andersen CL, Boisen MM, Sikora MJ, et al. The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer. Horm. Cancer 2018; 9(6): 399–407.
  9. Jiao Y, Lu B. Poorly differentiated mucinous carcinoma with signet ring cells in an ovarian endometriotic cyst: A case report. Diagn. Pathol 2019; 14(1): 73.
  10. Del Carmen MG, Sehdev AES, Fader AN, et al. Endometriosis-associated ovarian carcinoma: Differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer 2003; 98: 1658–1663.
  11. Akahane T, Sekizawa A, Okuda T, Kushima M., Saito H, Okai T. Disappearance of Steroid Hormone Dependency During Malignant Transformation of Ovarian Clear Cell Cancer. Int. J. Gynecol. Pathol 2005; 24(4): 369–376.
  12. Lai CR, Hsu CY, Chen YJ, Yen MS, Chao KC, Li AFY. Ovarian cancers arising from endometriosis: A microenvironmental biomarker study including ER, HNF1ß, p53, PTEN, BAF250a, and COX-2. J. Chin. Med. Assoc 2013; 76(11): 629–634.
  13. Penciu RC, Postolache I, Steriu L, et al. Is there a relationship in-between ovarian endometriosis and ovarian cancer? Immunohistochemical profile of four cases with coexisting ovarian endometriosis and cancer. Rom J Morphol Embryol 2020; 61: 157–165.
  14. Pavaleanu I, Lozneanu L, Balan RA, et al. Insights into molecular pathways of endometriosis and endometriosis-related ovarian carcinoma. Rom J Morphol Embryol 2021; 61(3): 739–749.
  15. Nezhat F, Cohen C, Rahaman J, Gretz H, Cole, P, Kalir, T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer 2002; 94(11): 2935–2940.
  16. de la Cuesta RS, Izquierdo M, Cañamero M, Granizo JJ, Manzarbeitia F. Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol 2004; 113(1): 87–93.
  17. Ma X, Hui Y, Lin L, Wu Y, Zhang X, Qin X. Possible relevance of tumor-related genes mutation to malignant transformation of endometriosis. Eur J Gynaecol Oncol 2016; 37(1): 89–94.
  18. Bayramodlu H, Duzcan E. Atypical epithelial changes and mutant p53 gene expression in ovarian endometriosis. Pathol Oncol Res 2001; 7(1): 33–38.
  19. Ogawa S, Kaku T, Amada S, et al. Ovarian Endometriosis Associated with Ovarian Carcinoma: A Clinicopathological and Immunohistochemical Study. Gynecol Oncol 2000; 77(2): 298–304.
  20. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Cumulative alterations of p27Kip1-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma. Histopathology 2010: 56(6): 740–749.
  21. Králíčková M, Laganà AS, Ghezzi F, Vetvička V. Endometriosis and risk of ovarian cancer: What do we know? Arch Gynecol Obstet 2020; 301(1): 1–10.
  22. Kajo K, Vallová M, Biró C, et al. Molekulová patológia endometriálneho karcinómu – prehľad. Cesk Patol 2015;51(2):65-73.
  23. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear- -cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 2011; 25(4): 615–624.
  24. Anglesio MS, Bashashati A, Wang YK, et al. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol 2015; 236(2): 201–209.
  25. Matsumoto T, Yamazaki M, Takahashi H, et al. Distinct β-catenin and PIK3CA Mutation Profiles in Endometriosis-Associated Ovarian Endometrioid and Clear Cell Carcinomas. Am J Clin Pathol 2015; 144: 452–463.
  26. Er TK, Su YF, Wu CC, et al. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer. J Mol Med 2016; 94(7): 835–847.
  27. Kato M, Takano M, Miyamoto M, et al. Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in puretype clear cell adenocarcinoma of the ovary. Mol Clin Oncol 2016; 5(4): 395–401.
  28. Stamp  JP,  Gilks  CB, Wesseling  M, et al. BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer. Int J Gynecol Cancer 2016; 26(5): 825–832.
  29. Ali-Fehmi R, Khalifeh I, Bandyopadhyay S, et al. Patterns of Loss of Heterozygosity at 10q23.3 and Microsatellite Instability in Endometriosis, Atypical Endometriosis, and Ovarian Carcinoma Arising in Association with Endometriosis. Int J Gynecol Pathol 2006; 25(3); 223–229.
  30. Suryawanshi S, Huang X, Elishaev E, et al. Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer. Clin Cancer Res 2014; 20: 6163–6174.
  31. Zhang C, Wang X, Anaya Y, et al. Distinct molecular pathways in ovarian endometrioid adenocarcinoma with concurrent endometriosis. Int J Cancer 2018; 143(10): 2505–2515.
  32. Amemiya S, Sekizawa A, Otsuka J, Tachikawa T, Saito H, Okai T. Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability. Int J Gynecol Obstet 2004; 86: 371–376.
  33. Anglesio MS, Papadopoulos N, Ayhan A, et al. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med 2017; 376(19): 1835–1848.
  34. Cochrane DR, Tessier-Cloutier B, Lawrence KM, et al. Clear cell and endometrioid carcinomas: Are their differences attributable to distinct cells of 772 origin? J Pathol 2017; 243(1): 26–36.
  35. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumors. Histopathology 1997; 30(3): 249-255.
Labels
Anatomical pathology Forensic medical examiner Toxicology
Rozloučení po čtrnácti letech ve funkci šéfredaktora a pohled do budoucna
Využití molekulární genetiky v diagnostice infekčních agens
Když jsem v prvním ročníku na medicíně přeřízl celý nervově cévní svazek, řekl jsem si, že ze mě neurochirurg asi nebude
MONITOR aneb nemělo by vám uniknout, že
Molecular detection of infectious agents in the pathology laboratory
16S, 18S gene, and ITS region Sequencing: Expanded Applications in Pathology Diagnostics and Research
Disseminated HSV1 infection in a newborn – case report
Article was published in

Czecho-Slovak Pathology

Issue 4
2024 Issue 4
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#